11.10.2026, 15:00
Einladung zur Festlichen Bläsermusik
15.10.2026, 15:00
Forschung in echt: Austausch macht Schule – Vertrauen stärken, Urteilskraft fördern
Wie können wir junge Menschen darin stärken, wissenschaftliche Informationen kritisch einzuordnen und fundierte Entscheidungen zu treffen? Am Beispiel der HPV-Impfung haben wir in dem Projekt Besuch...
more ...
15.10.2026, 17:00
Talk im Cube: Entrepreneurship Programs & Business Plan Development for Life Scientists
Join us for this edition of Talk in the Cube to explore - how life scientists can leverage entrepreneurship programs and - robust business plans that address market opportunities, regulatory requireme...
more ...
T-knife Therapeutics is one of the most successful start-ups in the biotech scene. Founded in 2018 as a spin-off of the Max Delbrück Center for Molecular Medicine (MDC) with the support of Charité – Universitätsmedizin Berlin, its mission is to develop therapies that can combat cancer with the help of patients’ immune systems. Over the course of many years, the research team led by Professor Thomas Blankenstein has worked towards genetically modifying human T cells in such a way that their receptors can target and destroy specific tumor cells. Using this unique technology, the first T-cell receptor gene therapy in Germany is now being tested in a clinical trial.
Why do some people get sick while others remain healthy? Which risk factors and protective mechanisms contribute to this? The large-scale German National Cohort (GNC) Health Study makes it possible to investigate in a whole new dimension which
The human immune system is trained to distinguish between “self” and “non-self” and to destroy foreign structures. By means of anchor molecules (receptors) of T cells, it recognizes antigens of bacteria or viruses and thus can target and
In many cases, it is not yet possible to treat muscle disorders because the causes of muscle loss (dystrophy) have not yet been sufficiently elucidated. This is true for the around 400 genetic muscle diseases, each of which is rare, but also for
In the level 1 perinatal center of HELIOS Klinikum Berlin-Buch, the midwife Susann Knöfel often cares for pregnant women with high blood pressure (hypertension), which may be indicative of a preeclampsia. Preeclampsia, a special form of
The prospect that the first clinical trials will lead to the successful treatment of patients inspires and motivates the team of OMEICOS Therapeutics GmbH. All previous data suggest that the scientists and founders have for the first time found a
Care manager Nicole Folesky organizes the smooth operation of the various university outpatient units on Campus Berlin-Buch – a place where clinical research and basic research are closely intertwined. The university outpatient units are part of
For Dr. Annette Isbruch, head obstetrician/gynecologist at HELIOS Klinikum Berlin-Buch, perinatology is a family tradition. Her mother worked in the same field as a doctor in the municipal hospital in Berlin-Buch. Since the HELIOS group took over
